Prevalence of UGT1A1*28 promoter polymorphism in the omani population: Implications for irinotecan treatment in GI cancer

被引：0
|
作者：
Al Ghoche, A. A. G. [1 ]
Al Zadjali, S. [2 ]
Pullanhi, A. [3 ]
Alfahdi, A. [3 ]
Al-Balushi, A. [2 ]
Al-Mahrouqi, N. [2 ]
Abu Omar, R. [3 ]
Salman, B. [4 ]
Almoundhri, M. [1 ]
机构：
[1] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Oncol Dept, Muscat, Oman
[2] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Res Labs, Muscat, Oman
[3] Sultan Qaboos Univ Hosp, Muscat, Oman
[4] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Pharm Dept, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
525P
引用
收藏
页码：S208 / S209
页数：2
相关论文
共 50 条
  • [21] UGT1A1*28 polymorphism and vomiting in advanced colorectal cancer.
    El Bastawisy, Ahmed El Saied
    El-Zeiny, Amany
    Farid, Samar
    Bahnasy, Abeer
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] UGT1A1*28 genotyping reduces irinotecan toxicity costs
    Reactions Weekly, 2017, 1635 (1) : 12 - 12
  • [23] Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
    Satoh, Taroh
    Ura, Takashi
    Yamada, Yasuhide
    Yamazaki, Kentaro
    Tsujinaka, Toshimasa
    Munakata, Masaki
    Nishina, Tomohiro
    Okamura, Shu
    Esaki, Taito
    Sasaki, Yasutsuna
    Koizumi, Wasaburo
    Kakeji, Yoshihiro
    Ishizuka, Naoki
    Hyodo, Ichinosuke
    Sakata, Yuh
    CANCER SCIENCE, 2011, 102 (10) : 1868 - 1873
  • [24] UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof
    Mani S.
    AAPS PharmSci, 3 (3):
  • [25] UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof
    Mani, S
    AAPS PHARMSCI, 2001, 3 (03): : U30 - U31
  • [26] Severe Neonatal Hyperbilirubinemia and UGT1A1 Promoter Polymorphism
    Travan, Laura
    Lega, Sara
    Crovella, Sergio
    Montico, Marcella
    Panontin, Elisa
    Demarini, Sergio
    JOURNAL OF PEDIATRICS, 2014, 165 (01): : 42 - 45
  • [27] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Fei-fei Han
    Chang-long Guo
    Dan Yu
    Jin Zhu
    Li-li Gong
    Guang-run Li
    Ya-li Lv
    He Liu
    Guang-yu An
    Li-hong Liu
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 779 - 788
  • [28] Heterozygosity for a polymorphism in the promoter region of the UGT1A1 gene
    Kaplan, M
    Hammerman, C
    Beutler, E
    JOURNAL OF HEPATOLOGY, 2001, 35 (01) : 148 - 149
  • [29] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Han, Fei-fei
    Guo, Chang-long
    Yu, Dan
    Zhu, Jin
    Gong, Li-li
    Li, Guang-run
    Lv, Ya-li
    Liu, He
    An, Guang-yu
    Liu, Li-hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 779 - 788
  • [30] UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene
    Lusin, T. Trdan
    Mrhar, A.
    Trontelj, J.
    PHARMAZIE, 2015, 70 (02): : 94 - 96
12345